Released: January 14, 2022
Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Lung Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)
The FY22 Defense Appropriations Bill has not been signed into law. Although FY22 funds have not been appropriated for the Lung Cancer Research Program (LCRP), the LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the government.
The FY22 Defense Appropriations Act is anticipated to provide funding for the LCRP to support innovative, high-impact lung cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).
The LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the Government. The FY22 LCRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.
Applications submitted to the FY22 LCRP must address one or more of the following Areas of Emphasis:
- Identify innovative strategies for the prevention of the occurrence of lung cancer.
- Identify innovative strategies for the screening and early detection of lung cancer.
- Understand the molecular mechanisms of initiation and progression to lung cancer.
- Understand contributors to lung cancer development other than tobacco.
- Identify innovative strategies for the treatment of lung cancer.
- Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
- Develop or optimize biomarkers to assist with therapeutic decision-making.
- Understand mechanisms of resistance to treatment (primary and secondary).
- Identify innovative strategies for comprehensive lung cancer care (clinical management/surveillance/symptom management/palliative care).
- Understand factors and/or develop implementation strategies to address health disparities in lung cancer.
Relevance to Military Health: The LCRP seeks to support research that is relevant to the healthcare needs of military Service Members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the DHP and FY22 LCRP during programmatic review. Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:
- Use of military of Veteran populations, biospecimens, data/databases, or programs in the proposed research.
- Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators.
- Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population.
- Explanation of how the project addresses an aspect of lung cancer that has a direct relevance to military Service Members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco.
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Concept Award||Investigators at all academic levels.||
New Options for FY22
|Career Development Award||
Principal Investigator: Independent investigators at the level of Assistant Professor, Instructor, or equivalent must be within 5 years of first faculty appointment.
Mentor: At or above the level of Associate Professor (or equivalent); have a proven publication and funding record in lung cancer research.
|Idea Development Award||
Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent) or
New Investigators: Investigators that meet the following criteria by the application submission deadline date:
|Investigator-Initiated Translational Research Award||Independent investigators at or above the level of Assistant Professor (or equivalent)||
|Clinical Translational Research Partnership Award||Investigators at or above the level of Assistant Professor (or equivalent)||
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Friday, January 14, 2022